The other case with BRAF V600E mutations was treated with vemurafenib after failure of etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH) chemotherapy, showing significant decrease in tumor size and metabolic activity [68]. This evidence concerns the gene BRAF and neoplasm.